NasdaqGS:MGNX

Stock Analysis Report

Executive Summary

MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States.

Snowflake

Fundamentals

Flawless balance sheet and fair value.

Share Price & News

How has MacroGenics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.3%

MGNX

3.1%

US Biotechs

1.8%

US Market


1 Year Return

-41.3%

MGNX

-7.9%

US Biotechs

7.3%

US Market

Return vs Industry: MGNX underperformed the US Biotechs industry which returned -7.9% over the past year.

Return vs Market: MGNX underperformed the US Market which returned 7.3% over the past year.


Shareholder returns

MGNXIndustryMarket
7 Day-3.3%3.1%1.8%
30 Day-15.5%-2.4%-0.7%
90 Day-25.1%-0.8%0.06%
1 Year-41.3%-41.3%-7.1%-7.9%9.7%7.3%
3 Year-57.0%-57.0%14.2%10.3%46.3%36.9%
5 Year-42.6%-42.6%0.07%-4.8%64.5%46.5%

Price Volatility Vs. Market

How volatile is MacroGenics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MacroGenics undervalued compared to its fair value and its price relative to the market?

44.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: MGNX ($11) is trading below our estimate of fair value ($19.98)

Significantly Undervalued: MGNX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MGNX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: MGNX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate MGNX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MGNX is good value based on its PB Ratio (1.8x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is MacroGenics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

8.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MGNX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MGNX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MGNX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MGNX's revenue (46.1% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: MGNX's revenue (46.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: MGNX is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has MacroGenics performed over the past 5 years?

-39.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: MGNX is unprofitable, and losses have increased over the past 5 years at a rate of -39% per year.

Accelerating Growth: Unable to compare MGNX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MGNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: MGNX has a negative Return on Equity (-52.8%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: MGNX is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: MGNX is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is MacroGenics's financial position?


Financial Position Analysis

Short Term Liabilities: MGNX's short term assets ($287.6M) exceeds its short term liabilities ($49.5M)

Long Term Liabilities: MGNX's short term assets (287.6M) exceeds its long term liabilities (39.7M)


Debt to Equity History and Analysis

Debt Level: MGNX is debt free.

Reducing Debt: MGNX has not had any debt for past 5 years.


Balance Sheet

Inventory Level: MGNX has a low level of unsold assets or inventory.

Debt Coverage by Assets: MGNX's debt is covered by short term assets (assets are 80951358877054554.808090x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MGNX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MGNX has sufficient cash runway for 1.515569 years if free cash flow continues to reduce at historical rates of -29.1% each year.


Next Steps

Dividend

What is MacroGenics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.7%industryaverage2.0%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate MGNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MGNX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if MGNX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MGNX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MGNX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of MacroGenics's salary, the management and board of directors tenure and is there insider trading?

6.2yrs

Average management tenure


CEO

Scott Koenig (67yo)

18.1yrs

Tenure

US$5,205,733

Compensation

Dr. Scott Koenig, M.D., Ph.D., has been the President and Chief Executive Officer of Macrogenics, Inc. since September 2001. Dr. Koenig served as Senior Vice President of Research at MedImmune Inc., where  ...


CEO Compensation Analysis

Compensation vs. Market: Scott's total compensation ($USD5.21M) is above average for companies of similar size in the US market ($USD1.79M).

Compensation vs Earnings: Scott's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

6.2yrs

Average Tenure

54.5yo

Average Age

Experienced Management: MGNX's management team is seasoned and experienced (6.2 years average tenure).


Board Age and Tenure

6.1yrs

Average Tenure

61yo

Average Age

Experienced Board: MGNX's board of directors are considered experienced (6.1 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Scott Koenig (67yo)

    CEO, President & Director

    • Tenure: 18.1yrs
    • Compensation: US$5.21m
  • Ezio Bonvini (65yo)

    Senior VP of Research & Chief Scientific Officer

    • Tenure: 3.1yrs
    • Compensation: US$1.93m
  • Jim Karrels (52yo)

    Senior VP

    • Tenure: 11.4yrs
    • Compensation: US$1.88m
  • Lynn Cilinski (61yo)

    VP, Controller & Treasurer

    • Tenure: 16yrs
  • Eric Risser (46yo)

    Senior VP of Business Development & Portfolio Management and Chief Business Officer

    • Tenure: 3.1yrs
    • Compensation: US$1.88m
  • Anna Krassowska

    Vice President of Investor Relations & Corporate Communications

    • Tenure: 0yrs
  • Tom Spitznagel (52yo)

    Senior Vice President of BioPharmaceutical Development & Manufacturing

    • Tenure: 0yrs
  • Jon Wigginton (57yo)

    Senior VP of Clinical Development & Chief Medical Officer

    • Tenure: 6.2yrs
    • Compensation: US$1.98m
  • Jeffrey Peters (48yo)

    VP & General Counsel

    • Tenure: 2.3yrs

Board Members

  • Dave Stump (69yo)

    Director

    • Tenure: 6.1yrs
    • Compensation: US$189.07k
  • Ed Hurwitz (56yo)

    Director

    • Tenure: 15yrs
    • Compensation: US$187.44k
  • Ken Galbraith (56yo)

    Director

    • Tenure: 11.3yrs
    • Compensation: US$206.32k
  • Scott Koenig (67yo)

    CEO, President & Director

    • Tenure: 18.1yrs
    • Compensation: US$5.21m
  • Matt Fust (54yo)

    Director

    • Tenure: 5.6yrs
    • Compensation: US$204.32k
  • Paulo Costa (68yo)

    Chairman

    • Tenure: 6.1yrs
    • Compensation: US$231.06k
  • Scott Jackson (54yo)

    Director

    • Tenure: 2.8yrs
    • Compensation: US$192.69k
  • Jay Siegel (66yo)

    Director

    • Tenure: 1.9yrs
    • Compensation: US$178.32k
  • Karen Jean Ferrante (61yo)

    Director

    • Tenure: 2.8yrs
    • Compensation: US$189.07k

Company Information

MacroGenics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MacroGenics, Inc.
  • Ticker: MGNX
  • Exchange: NasdaqGS
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$537.828m
  • Shares outstanding: 48.89m
  • Website: https://www.macrogenics.com

Number of Employees


Location

  • MacroGenics, Inc.
  • 9704 Medical Center Drive
  • Rockville
  • Maryland
  • 20850
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MGNXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2013
M55DB (Deutsche Boerse AG)YesCommon StockDEEUROct 2013

Biography

MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates inclu ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/19 00:22
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.